FDA Approves Verzenio to Treat Advanced-Stage, HR+, HER2- BC

Moderators

FDA Approves Verzenio to Treat Advanced-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer
September 28, 2017
Verzenio has been approved by the FDA. Read more...

sbelizabeth

"The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient's hormones (endocrine therapy). Verzenio is approved to be given in combination with an endocrine therapy, called fulvestrant, after the cancer had grown on endocrine therapy. It is also approved to be given on its own, if patients were previously treated with endocrine therapy and chemotherapy after the cancer had spread (metastasized)."

So...Verzenio is NOT given as an initial neo-adjuvant therapy? It's only given AFTER locally advanced recurrence, or metastasis to other organs?

Anyone know?

lkc

Yes, it is only approved at this point for patients that have progressed on hormonal treatment. So , no as first line tx

sbelizabeth

Thanks, lkc. It's a step in the right direction, at least.

sbelizabeth

Thanks, lkc. It's a step in the right direction, at least.